Federated Hermes Inc. Invests $9.97 Million in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)

Key Points

• Federated Hermes Inc. invested approximately $9.97 million in Kestra Medical Technologies, acquiring 400,000 shares of the company during the 1st quarter.
• Kestra Medical has a current stock price of $15.38, with a 52-week range between $13.25 and $26.15, and a consensus analyst rating of "Moderate Buy."
• Recent price target reductions by analysts include Goldman Sachs lowering its target from $24.00 to $23.00, and Wells Fargo reducing its target from $28.00 to $27.00.

Federated Hermes Inc. bought a new position in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 400,000 shares of the company's stock, valued at approximately $9,968,000. Federated Hermes Inc. owned 0.78% of Kestra Medical Technologies at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Brown Advisory Inc. acquired a new position in shares of Kestra Medical Technologies in the first quarter valued at approximately $13,716,000. TD Asset Management Inc purchased a new position in Kestra Medical Technologies in the 1st quarter worth approximately $2,306,000. Jennison Associates LLC purchased a new position in shares of Kestra Medical Technologies during the first quarter valued at approximately $1,869,000. Finally, Caas Capital Management LP purchased a new position in shares of Kestra Medical Technologies in the first quarter worth approximately $1,470,000.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS opened at $15.38 on Friday. The firm's 50-day moving average is $17.51. The company has a current ratio of 6.72, a quick ratio of 6.72 and a debt-to-equity ratio of 0.20. Kestra Medical Technologies, Ltd. has a 52 week low of $13.25 and a 52 week high of $26.15.

Analyst Ratings Changes

KMTS has been the subject of several recent research reports. The Goldman Sachs Group decreased their price objective on Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating for the company in a report on Wednesday, April 16th. Wells Fargo & Company reduced their price target on shares of Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating for the company in a research report on Thursday, July 17th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Kestra Medical Technologies has a consensus rating of "Moderate Buy" and an average target price of $27.33.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.

Want to see what other hedge funds are holding KMTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.